ES75
TEAS SECTION 71 & 15 RECEIVED
06/16/2026
Back to search
Official data from USPTO
GENEVANT
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
GENEVANT
ST13
US500000079237909Class
5, 42, 44
Filing
79237909
Registration
5946662
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
41
Latest update
06/17/2026
Trademark type
Word
Nice classes
5, 42, 44
Filing date
04/23/2018
Registration date
12/31/2019
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
12/31/2019
Last transaction
06/17/2026
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
4
Owner type
99
Owner location
CH
Examiner
LEE, DOUGLAS
Law office
M40
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
Genevant Sciences GmbH
Representatives
Joyce M. Ferraro Fross Zelnick Lehrman & Zissu, P.C.
Technical classification
Nice Classes
Class 5Class 42Class 44
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceutical preparations for human use to treat genetic diseases and disorders and diseases and disorders associated with insufficient or faulty protein production or overproduction; biological preparations for medical or therapeutic use to treat genetic diseases and disorders and diseases and disorders associated with insufficient or faulty protein production or overproduction
Class 42
Scientific and technological services as well as research and design services relating theretoscientific research and development and product research and development; biomedical and pharmaceutical research services; research in the field of therapeutic biological and pharmaceutical preparations; pharmaceutical research and development; providing information relating to scientific research in the field of pharmaceutical and biomedicine
Class 44
Provision of health information and medical information; provision of information concerning the diagnosticprophylactic and therapeutic properties of pharmaceutical and biological preparations for prevention and treatment of diseasesdisorders and pathologies
Publications
History of USPTO decisions and trademark events.
41 publications found
REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
12/31/2024
NREP
NEW REPRESENTATIVE AT IB RECEIVED
10/11/2024
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
05/08/2020
FICS
FINAL DISPOSITION NOTICE SENT TO IB
04/16/2020
FIMP
FINAL DISPOSITION PROCESSED
04/16/2020
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
03/31/2020
R.PR
REGISTERED-PRINCIPAL REGISTER
12/31/2019
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
10/15/2019
PUBO
PUBLISHED FOR OPPOSITION
10/15/2019
GPNX
NOTIFICATION PROCESSED BY IB
10/12/2019
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
09/25/2019
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
09/25/2019
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
09/25/2019
ALIE
ASSIGNED TO LIE
09/12/2019
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
09/11/2019
XAEC
EXAMINER'S AMENDMENT ENTERED
09/09/2019
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
09/09/2019
GNEA
EXAMINERS AMENDMENT E-MAILED
09/09/2019
CNEA
EXAMINERS AMENDMENT -WRITTEN
09/09/2019
GNFN
NOTIFICATION OF FINAL REFUSAL EMAILED
03/09/2019
GNFR
FINAL REFUSAL E-MAILED
03/09/2019
CNFR
FINAL REFUSAL WRITTEN
03/09/2019
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
03/05/2019
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
03/04/2019
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
03/04/2019
ATRV
ATTORNEY REVIEW COMPLETED
12/07/2018
CREV
CORRECTION FROM IB ENTERED - ATTORNEY REVIEW REQUIRED
12/07/2018
CRCV
CORRECTION TRANSACTION RECEIVED FROM IB
11/23/2018
RFNP
REFUSAL PROCESSED BY IB
10/19/2018
NREP
NEW REPRESENTATIVE AT IB RECEIVED
10/11/2018
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
09/04/2018
RFRR
REFUSAL PROCESSED BY MPU
09/04/2018
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
08/30/2018
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
08/18/2018
CNRT
NON-FINAL ACTION WRITTEN
08/17/2018
MAFR
APPLICATION FILING RECEIPT MAILED
08/14/2018
DOCK
ASSIGNED TO EXAMINER
08/13/2018
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
08/08/2018
LIMI
LIMITATION FROM ORIGINAL APPLICATION ENTERED
08/07/2018
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
08/02/2018
Continuous trademark protection
Get notified about every new filing that threatens GENEVANT or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.